OPINION REVIEW

92  Could gastrointestinal tumor-initiating cells originate from cell-cell fusion in vivo?

ORIGINAL ARTICLE

Basic Study

109  Influence of the heat irrigating effect of radiofrequency ablation on regional liver tissue in Bama miniature pigs
Feng J, Wang S, Jiang K

Clinical and Translational Research

119  Total neoadjuvant therapy vs standard therapy of locally advanced rectal cancer with high-risk factors for failure
Tuta M, Boc N, Breclj E, Peternel M, Velenik V

META-ANALYSIS

131  Outcomes of curative esophageal cancer surgery in elderly: A meta-analysis
Baranov NS, Slootmans C, van Workum F, Klarenbeek BR, Schoon Y, Rosman C

CASE REPORT

147  Rare common bile duct metastasis of breast cancer: A case report and literature review
Tang J, Zhao GX, Dong SS, Xu M
ABOUT COVER
Monjur Ahmed, FACC, FACP, FASGE, FRCP, MD, MRCP, Associate Professor, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Thomas Jefferson University, Philadelphia, PA 19107, United States

AIMS AND SCOPE
The primary aim of World Journal of Gastrointestinal Oncology (WJGO, World J Gastrointest Oncol) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, etc.

INDEXING/ABSTRACTING
The WJGO is now indexed in Science Citation Index Expanded (also known as SciSearch®), PubMed, PubMed Central, and Scopus. The 2020 edition of Journal Citation Reports® cites the 2019 impact factor (IF) for WJGO as 2.898; IF without journal self cites: 2.880; 5-year IF: 3.316; Ranking: 143 among 244 journals in oncology; Quartile category: Q3; Ranking: 55 among 88 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO’s CiteScore for 2019 is 2.0 and Scopus CiteScore rank 2019: Gastroenterology is 86/137.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Jia-Hui Li; Production Department Director: Xiang Li; Editorial Office Director: Ya-Juan Ma.

NAME OF JOURNAL
World Journal of Gastrointestinal Oncology

ISSN
ISSN 1948-5204 (online)

LAUNCH DATE
February 15, 2009

FREQUENCY
Monthly

EDITORS-IN-CHIEF
Rosa M Jimenez Rodriguez, Pashtoon Kasi, Monjur Ahmed

EDITORIAL BOARD MEMBERS

PUBLICATION DATE
February 15, 2021

COPYRIGHT
© 2021 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com

© 2021 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
E-mail: bpgoffice@wjgnet.com  https://www.wjgnet.com
Rare common bile duct metastasis of breast cancer: A case report and literature review

Jie Tang, Guang-Xi Zhao, Shuang-Shuang Deng, Ming Xu

ORCID number: Jie Tang 0000-0001-9481-1741; Guang-Xi Zhao 0000-0003-2495-0847; Shuang-Shuang Deng 0000-0003-2548-0621; Ming Xu 0000-0003-1785-1787.

Author contributions: Tang J and Zhao GX reviewed the patient information and wrote the manuscript; Deng SS reviewed the pathologic findings and wrote the manuscript; Xu M designed, reviewed, and wrote the manuscript; All authors have read and approved the final manuscript.

Supported by Top-level Clinical Discipline Project of Shanghai Pudong, No. PWYgf2018-04.

Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.

Conflict-of-interest statement: The authors declare that they have no conflicts of interest.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and

Abstract

BACKGROUND
Breast cancer is the most common tumor in women, and about one-third of cases develop metastatic disease. However, metastatic breast cancer rarely invades the common bile duct (CBD) directly without involving the liver, and involvement of the gastrointestinal tract is rare. Cases of such metastases pose a particular diagnostic challenge.

CASE SUMMARY
A 55-year-old female presented to the Department of Gastroenterology with complaint of a 2 mo history of right upper abdominal pain accompanied by pain in the right back, aggravated after eating greasy diet. The patient had received a diagnosis of breast cancer 3 years prior. Physical examination showed obvious superficial protuberant erythema on the left neck and chest skin, with slight tenderness and burning sensation. Endoscopic retrograde cholangiopancreatography showed an obstruction at the end of the CBD. Histopathology of the CBD and symptomatic skin biopsies showed positivity for cytokeratin 7 and trans-acting T-cell-specific transcription factor breast cancer biomarkers. A cancer embolus was also found in the skin vasculature. Accordingly, the diagnosis of breast cancer metastases to the skin and biliary ducts was made. A plastic biliary stent was placed, which relieved the right upper abdominal pain and protected against unnecessary hepatectomy surgery.

CONCLUSION
Although rare, biliary metastasis should be considered in patients with bile duct stenosis and a history of breast cancer.
fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/License s/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Specialty type:** Oncology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**
- Grade A (Excellent): 0
- Grade B (Very good): B, B
- Grade C (Good): 0
- Grade D (Fair): 0
- Grade E (Poor): 0

**Received:** November 6, 2020

**Peer-review started:** November 6, 2020

**First decision:** November 30, 2020

**Revised:** December 11, 2020

**Accepted:** December 26, 2020

**Article in press:** December 26, 2020

**Published online:** February 15, 2021

**P-Reviewer:** Kimura K

**S-Editor:** Fan JR

**L-Editor:** Filipodia

**P-Editor:** Li JH

---

**Key Words:** Breast cancer; Common bile duct; Metastases; Plastic stent; Prognosis; Case report

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Breast cancer is the most common tumor in women, and about one-third of cases develop metastatic disease. However, metastatic breast cancer rarely invades the common bile duct (CBD) directly without involving the liver, and involvement of the gastrointestinal tract is rare. We report a case of CBD metastasis from breast cancer that was diagnosed according to findings from endoscopic retrograde cholangiopancreatography imaging and histopathology of CBD and symptomatic skin biopsies. This case highlights the importance of making an accurate diagnosis before undertaking an operative approach. Although CBD metastasis of breast cancer is rare, it should not be completely ignored.

**Citation:** Tang J, Zhao GX, Deng SS, Xu M. Rare common bile duct metastasis of breast cancer: A case report and literature review. World J Gastrointest Oncol 2021; 13(2): 147-156

**URL:** https://www.wjgnet.com/1948-5204/full/v13/i2/147.htm

**DOI:** https://dx.doi.org/10.4251/wjgo.v13.i2.147

---

**INTRODUCTION**

Breast cancer is the most common tumor in women and about one-third of cases will progress to metastatic disease, which is the leading cause of cancer-related death. Only 5%-10% of newly diagnosed breast cancer patients present with distant metastases; more troubling, the risk of developing metastatic disease is high among patients with localized primary disease following successful primary tumor resection and adjuvant therapy. It is estimated that up to 30% of node-negative breast cancer patients will develop metastatic disease, despite receiving standard treatment.

Breast cancer metastasis includes contiguous, lymphatic, and hematogenous forms of spread. While hematogenous spread of breast cancer can target any site in the human body, the most common sites are bone, lung, lymph nodes, liver, and brain. Metastasis to the digestive system, kidney, and retroperitoneal organs is rare, and to the biliary system is remarkably rare. Widespread liver metastases can compress or infiltrate the bile duct, which may lead to obstructive jaundice, while a direct metastatic involvement of the extrahepatic bile duct in the absence of hepatic lesions is exceptional.

We describe, herein, a special case of secondary tumor of the common bile duct (CBD) from a primary breast cancer tumor that had been treated by operation 3 years earlier. Our review of the literature highlighted that this diagnosis may be difficult and controversial in rare cases. For early diagnosis, endoscopy and detailed pathological analysis are necessary, which may help prevent unnecessary surgical intervention.

---

**CASE PRESENTATION**

**Chief complaints**

A 55-year-old female presented to the Department of Gastroenterology (Shanghai East Hospital, Shanghai, China) with complaint of right upper abdominal pain lasting over a 2 mo period that was accompanied by pain in the right back and aggravated after eating greasy diet.

**History of present illness**

The patient’s symptoms started 2 mo prior, with recurrent episodes of right upper abdominal pain.

**History of past illness**

The patient had been diagnosed with breast cancer 3 years prior but had an
unremarkable medical history otherwise.

Physical examination
Physical examination revealed mild tenderness in the right upper quadrant of the abdomen. Superficial protuberant erythema with clear margins were observed on the left neck and chest; the patient indicated a burning sensation and slight tenderness associated with the erythema.

Laboratory examinations
Laboratory tests upon admission showed elevated gamma-glutamyl transpeptidase (238 IU/L; normal range: 10-60 IU/L) but normal level of alkaline phosphatase (67 IU/L) and negative findings for inflammatory biomarkers. All blood tumor markers (alpha-fetoprotein: 2.01 ng/mL; carcinoembryonic antigen: 1.71 ng/mL; cancer antigen-125: 12.1 U/mL; cancer antigen-199: 9.26 U/mL; and cancer antigen-135: 14.3 U/mL) were within normal ranges.

Imaging examinations
Magnetic resonance cholangiopancreatography revealed enlarged head of the pancreas, narrowed CBD within the pancreas head, and slightly dilated upper bile ducts. Ultrasound gastroscopy revealed changes indicative of chronic pancreatitis, widening of the bile duct wall, and immunoglobulin G (IgG)4-related cholangitis. Subsequent laboratory tests, however, showed the IgG-4 level to be within the normal range, excluding the possibility of IgG4-related cholangitis. Abdominal enhanced magnetic resonance imaging showed that the wall of the CBD was thickened and became obviously enhanced with contrast agent. The coronal view showed dilation of the upper segment of the CBD, with rough tissue wall and narrowing of the lower segment. Nodular thickening was also seen (localized) in the lower segment of the CBD. Endoscopic retrograde cholangiopancreatography (ERCP) showed an obstruction at the end of the CBD. Biopsies were taken from the affected tissues (CBD end and symptomatic skin lesions). Bone scan showed metastases in the left third rib and the eighth vertebral body.

Further diagnostic work-up
Histopathology results for the biopsied CBD and skin of left neck and chest were: Cytokeratin 7 (+); trans-acting T-cell-specific transcription factor (+); estrogen receptor (ER) (-); progesterone receptor (PR) (-); and human epidermal growth factor receptor-2 (HER2) (-). Morphological characteristics were assessed, and a cancer embolus was found in the skin vasculature.

FINAL DIAGNOSIS
Metastases of breast cancer to the skin and biliary ducts.

TREATMENT
After undergoing ERCP placement of a plastic stent for systemic chemotherapy, the patient was referred to an oncologist who ordered a treatment course of gemcitabine (1000 mg, administered on day 1 and day 8) and cisplatin (30 mg, administered on day 1 to day 3).

OUTCOME AND FOLLOW-UP
The patient eventually died of multiple organ failure caused by severe infection after systemic chemotherapy.

DISCUSSION
Invasive breast carcinoma of no special type is the most common histological type of breast cancer, accounting for 75%-80% of all invasive breast cancer cases.
Gastrointestinal tract involvement is rare, accounting for only about 10% of all cases, but usually occurs in invasive lobular carcinoma\(^1\). Through literature review, we found reports of 30 cases of metastatic breast cancer involving the bile ducts, including 7 cases involving CBD\(^1\)-\(^9\), 20 cases involving extrahepatic duct\(^9\)-\(^21\) or lymph nodes extending directly into bile ducts\(^9\)-\(^22\) and ampulla of Vater, and 3 cases classified as uncertain\(^2\) (Table 1). In these cases, the time interval between the diagnosis of breast cancer and the secondary tumor was as long as 21 years and as short as 2 years. Preoperative diagnosis was achieved in only 4 cases, and the others were treated surgically. Rego \textit{et al.}\(^1\) reported on 2 patients with abnormal ampulla and distal CBD stenosis detected by ERCP, with a diagnosis of breast metastasis confirmed by immunohistochemistry before surgical treatment. Budimir \textit{et al.}\(^1\) reported another case in which ERCP detected CBD stenosis, after which brush aspiration was performed for subsequent cytological analysis. Finally, Cochrane \textit{et al.}\(^3\) reported a case in which endoscopic ultrasound revealed a mass in the mid-portion of the CBD, with fine-needle aspiration biopsy demonstrating metastatic breast cancer.

Patients with metastatic breast cancer involving the bile ducts may experience abdominal discomfort, upper gastrointestinal bleeding, jaundice and related symptoms, such as pruritus or alterations in stool and urine\(^2\); these nonspecific clinical symptoms, being similar to the presentation of primary tumors, complicate the diagnostic process. Moreover, in most cases, there is a long interval between the diagnosis of the primary tumor and the development of metastatic tumors affecting biliary tract function, which poses a further challenge to suspicion of a relationship between the historical breast cancer event and the presenting biliary disease\(^1\)-\(^3\),\(^2\). Endoscopic diagnosis may be difficult, due to implantation of the metastatic cells in the submucosa. Coletta \textit{et al.}\(^2\) reported that breast cancer metastasis could target the

---

**Figure 1** Magnetic resonance cholangiopancreatography. Findings of dilatation of the common bile duct, stenosis of the distal common bile duct, and density shadow of soft tissue are indicated by an arrow.

**Figure 2** Endoscopy findings. Ultrasound gastroscopy revealed widening of the bile duct wall (arrows).
Table 1 Reported cases of bile duct metastasis of breast cancer

<table>
<thead>
<tr>
<th>Ref.</th>
<th>Cases, n</th>
<th>Location of secondary tumor</th>
<th>Therapy</th>
<th>Time interval between diagnosis of primary tumor and metastasis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Popp et al.²⁸, 1979</td>
<td>1</td>
<td>CBD</td>
<td>Surgical bypass plus chemotherapy</td>
<td>Average 40 mo</td>
</tr>
<tr>
<td>Titus et al.²⁹, 1997</td>
<td>1</td>
<td>Distal bile duct</td>
<td>Pancreatectoduodenectomy</td>
<td>Undetermined</td>
</tr>
<tr>
<td>Stoeckeler et al.³⁰, 2007</td>
<td>1</td>
<td>Distal bile duct</td>
<td>Pancreatectoduodenectomy</td>
<td>Undetermined</td>
</tr>
<tr>
<td>Rego et al.³¹, 2009</td>
<td>2</td>
<td>Ampulla of Vater and CBD</td>
<td>Surgery and palliative chemotherapy</td>
<td>2 yr</td>
</tr>
<tr>
<td>Cochrane et al.³², 2015</td>
<td>1</td>
<td>CBD</td>
<td>Aplastic stent placed, chemotherapy and endocrine therapy</td>
<td>21 yr</td>
</tr>
<tr>
<td>Budimir et al.³³, 2015</td>
<td>1</td>
<td>CBD</td>
<td>Metal stent implantation and aromatase inhibitors</td>
<td>6 yr</td>
</tr>
<tr>
<td>Popp et al.³⁴, 1979</td>
<td>6</td>
<td>Extrahepatic lymph nodes</td>
<td>Radical and palliative surgery, transhepatic drainage, radiation, chemotherapy</td>
<td>Average 40 mo</td>
</tr>
<tr>
<td>Kopelson et al.³⁵, 1980</td>
<td>6</td>
<td>Extrahepatic duct</td>
<td>Radical and palliative surgery, radiation, chemotherapy</td>
<td>Undetermined</td>
</tr>
<tr>
<td>Engel et al.³⁶, 1980</td>
<td>2</td>
<td>Extrahepatic duct, lymph nodes</td>
<td>Biliary tract resection and choledochojunostomy</td>
<td>Undetermined</td>
</tr>
<tr>
<td>Franco et al.³⁷, 1987</td>
<td>2</td>
<td>Proximal bile duct, bifurcation</td>
<td>Bile duct resection, double choledochojunostomy</td>
<td>6 and 8 yr respectively</td>
</tr>
<tr>
<td>Pappo et al.³⁸, 1991</td>
<td>1</td>
<td>Extrahepatic, intra and extraluminal</td>
<td>Bile duct resection, choledochojunostomy, cholecystectomy</td>
<td>2 yr</td>
</tr>
<tr>
<td>Feliu Villaró et al.³⁹, 1995</td>
<td>1</td>
<td>Extrahepatic intraluminal</td>
<td>Undetermined</td>
<td>Undetermined</td>
</tr>
<tr>
<td>Pappo et al.⁴⁰, 1996</td>
<td>1</td>
<td>Extrahepatic intraluminal</td>
<td>Biliary tract resection and choledochojunostomy</td>
<td>Undetermined</td>
</tr>
<tr>
<td>Coletta et al.⁴¹, 2014</td>
<td>1</td>
<td>Extrahepatic bile ducts</td>
<td>Cholecystectomy, extrahepatic biliary resection, and double hepaticojunostomy</td>
<td>13 yr</td>
</tr>
<tr>
<td>Rabin et al.⁴², 1979</td>
<td>3</td>
<td>Undetermined</td>
<td>Undetermined</td>
<td>Undetermined</td>
</tr>
</tbody>
</table>

CBD: Common bile duct.

extrahepatic bile duct without involvement of the lumen or duct mucosa. ERCP sensitivity ranges from 25% to 50% for masses near the hepatic hilum, and negative finding for biopsied tissues is estimated to occur in > 30% of cases. Thus, the combination of ultrasound-guided biopsy and immunohistochemical analysis plays a key role in the diagnosis of this rare type of secondary tumor.

Early identification and surgical resection of cholangiocarcinoma have been shown to improve the 5-year overall survival. In the case of primary malignant bile duct tumors, clinicians are likely to recommend surgery, but for patients with metastatic breast cancer, surgery is generally not considered clinically beneficial. Treatments for metastatic breast cancer are guided by multiple factors, most importantly the expression status of ER, PR, and HER2, treatment history, and prognostic indicators (i.e., short disease-free interval, presence of visceral metastases, performance status, and degree of symptoms). For example, patients with hormone receptor-positive status are expected to benefit from hormone therapy, whereas those with HER2-positive disease are treated with targeted agents (trastuzumab and lapatinib) in conjunction with chemotherapy. In contrast, treatments of patients with triple-negative breast cancer only depend on cytotoxic chemotherapy. Discrimand ER, PR, or HER2 expression status between primary tumors and metastases has been reported. In addition, the conversion to negative receptor status is, on average, higher than that of positive conversion (24% vs 14% for ER; 46% vs 15% for PR; 13% vs 5% for HER2). Two explanations have been put forth for this observation. The first involves technical issues that result in poor reproducibility of immunohistochemistry techniques. The second involves tumor heterogeneity (i.e.,
subpopulations of cells within the primary tumor and its metastases, having distinct genotypes and phenotypes and possibly different biological behaviors\[31\]. Receptor status of breast cancer may indicate both the prognosis and risk of recurrence; for example, ER-positive tumors display protracted metastasis latency periods and frequently metastasize to the bone\[32-35\]. In our case, CBD metastasis of breast cancer occurred 3 years after surgical treatment, with multiple bone metastases in addition. Expression of the nuclear protein Ki-67 has been shown to correlate with the proliferative rate of tumor cells and this biomarker is used clinically as an independent prognostic biomarker in primary breast cancer, especially among patients with ER (+) tumors\[36,37\]. Therefore, a biopsy of suspected breast cancer metastases would be necessary to determine the appropriate management of the disease.

In general, patients with pancreaticobiliary malignancies, metastatic disease and external biliary compression by lymph nodes should be implanted with plastic or self-expanding metal stents to both relieve related jaundice and abdominal pain symptoms and to improve the overall prognosis\[11\]. Surgical bypass or biliary stenting is reported to extend survival to over 1 year, in comparison to un-intervened cases of liver metastases, for whom mean survival is only about 1 mo\[11\]. Although many previous reports have indicated the superiority of a metal stent for malignant distal biliary obstruction\[38\], we generally prefer to use plastic stents to relieve symptoms before pathological diagnosis is obtained. Thus, only after our patient underwent ERCP placement of a plastic stent was she referred to the oncology department for systemic chemotherapy.

**CONCLUSION**

In conclusion, we report a special breast cancer case of direct metastasis to the CBD. Although this situation is rare, the possibility of biliary metastasis should be considered in the differential diagnosis of the bile duct stenosis for patients with a history of breast cancer, to avoid unnecessary hepatectomy. The differential diagnosis of cholangiocarcinoma is very important, with advanced endoscopic techniques and pathological diagnosis playing an important role in such.
Figure 4 Endoscopy findings. A: Endoscopic retrograde cholangiopancreatography showed dilatation of the common bile duct and stenosis of the distal common bile duct (arrow); B: Edema of the ampulla; C: Implanted plastic stent.

Figure 5 Bone scan findings. A: Metastasized tumors in the left third rib; B: Metastasized tumors in the eighth vertebral body.
Figure 6 Histopathology of biopsies of the common bile duct and the skin of left neck and chest. A: Cancer cells were found to have infiltrated the glandular duct of the common bile duct (CBD); B and C: Low-power magnifications (B: 2’, C: 40’) demonstrating cancer embolus in the vasculature of the skin; D: Positive immunohistochemistry (IHC) staining for CD34 in the cancer embolus areas; E and F: Strong positive IHC staining for cytokeratin (CK) 7 and trans-acting T-cell-specific transcription factor (GATA-3) in the CBD; G: Strong positive IHC staining for CK7 in the skin of left neck and chest; H: Strong positive IHC staining for GATA3 in the skin of left neck and chest.

REFERENCES


Tang J et al. Bile duct metastases from breast cancer

